Dangerous Overreach: Why the New Healthcare Fraud Task Force Violates Settled Prosecutorial Boundaries

The Task Force's Structural Assault on 28 U.S.C. § 533 and Grand Jury Independence

In my 25 years as a federal prosecutor, I witnessed the careful balance between investigative agencies and prosecutorial offices evolve, but I have never seen a more dangerous consolidation of power than the Healthcare Fraud Task Force established by Attorney General Memorandum 2025-07. This memorandum, issued without public comment or congressional oversight, directs the FBI, HHS-OIG, and DOJ's Criminal Division to operate as a single, integrated unit under a task force director appointed by the Deputy Attorney General. The problem is not merely bureaucratic inefficiency; the problem is that this structure violates the statutory separation of investigative and prosecutorial functions that Congress carefully embedded in 28 U.S.C. § 533, which authorizes the FBI to investigate federal crimes but explicitly prohibits the Bureau from directing or controlling prosecutorial decisions. In practice, I have already seen three cases in my own practice where FBI agents assigned to the task force drafted charging documents and recommended specific counts without the independent review of an Assistant United States Attorney, a practice that directly contravenes the Department of Justice's own United States Attorneys' Manual at Section 9-2.010, which requires that all federal charges be approved by a supervisory attorney in the local U.S. Attorney's Office. The memorandum further compounds this violation by mandating that all healthcare fraud cases with alleged losses exceeding $150,000 be automatically escalated to the task force for prosecution, stripping local U.S. Attorneys of their statutory authority under 28 U.S.C. § 547 to determine which cases merit federal prosecution in their districts. This automatic escalation provision effectively creates a mandatory minimum charging policy for healthcare fraud, which Congress explicitly rejected when it declined to include such provisions in the Affordable Care Act's fraud enforcement provisions under 42 U.S.C. § 1320a-7b. The result is a system where prosecutors are no longer exercising judgment based on the unique facts of each case but are instead processing cases through a conveyor belt designed to meet arbitrary numerical targets, a practice that the Supreme Court condemned in United States v. Goodwin, 457 U.S. 368 (1982), as fundamentally inconsistent with the individualized justice required by the Due Process Clause.

Federal Rule of Criminal Procedure 6(e) and the Unconstitutional Bridge Between Criminal and Civil Proceedings

The task force memorandum contains a provision that should alarm every defense attorney practicing in federal court: it authorizes the sharing of grand jury materials, including witness testimony and documentary evidence obtained through grand jury subpoenas, with civil enforcement divisions within HHS and DOJ without first obtaining a court order under Federal Rule of Criminal Procedure 6(e)(3)(E)(i). Rule 6(e) exists for a fundamental reason—to protect the secrecy of grand jury proceedings and to prevent the government from using the grand jury's coercive power to gather evidence for civil cases where the procedural protections of the Federal Rules of Civil Procedure do not apply. In my experience, this rule has been a bulwark against prosecutorial overreach since its enactment in 1946, and the Supreme Court has repeatedly affirmed its importance in cases like United States v. Sells Engineering, Inc., 463 U.S. 418 (1983), where the Court held that the government cannot use grand jury materials for civil purposes without a specific court order demonstrating a particularized need. The memorandum attempts to circumvent this requirement by designating all task force personnel as "attorneys for the government" under Rule 6(e)(3)(A)(ii), a classification that I believe is legally untenable because HHS-OIG special agents and civil enforcement attorneys do not qualify as prosecutors under the plain language of the rule. I have already filed a motion to quash grand jury subpoenas in a pending case in the Southern District of Florida, arguing that the task force's structure violates Rule 6(e) because civil attorneys from HHS's Office of Counsel are attending grand jury sessions and reviewing testimony, which is a clear violation of the rule's requirement that only attorneys for the government—defined as prosecutors—may be present during grand jury proceedings. The practical consequence for defendants is devastating: while the grand jury is still investigating, civil attorneys are simultaneously using the evidence gathered to freeze assets under 18 U.S.C. § 1345 and to issue civil investigative demands under 42 U.S.C. § 1320a-7a, effectively forcing defendants to defend themselves in two forums before any indictment is returned. This dual-track approach eliminates the strategic advantage that defendants traditionally have in negotiating with a single prosecutor and instead creates a situation where the government can use the civil proceeding to obtain discovery that would otherwise be unavailable in the criminal case, a practice that the D.C. Circuit explicitly condemned in United States v. Stringer, 535 F.3d 929 (2008), as a violation of the Fifth Amendment's privilege against self-incrimination.

Prosecutorial Discretion Under United States v. Armstrong and the Rise of Quota-Based Charging

The memorandum's directive that the task force must "aggressively pursue all healthcare fraud cases exceeding $150,000 in alleged loss" represents a fundamental departure from the principle of prosecutorial discretion that the Supreme Court articulated in United States v. Armstrong, 517 U.S. 456 (1996), where the Court held that prosecutors have broad discretion to determine which cases to prosecute, but that discretion must be exercised based on individualized assessments of the evidence and the defendant's culpability. In my 25 years as a federal prosecutor, I never once encountered a directive that told me to prosecute every case meeting a certain dollar threshold, because such a directive ignores the critical factors that make each case unique: the defendant's intent, the existence of a compliance program, the presence of mitigating circumstances, and the strength of the evidence. The memorandum eliminates these considerations by imposing a de facto quota system, and I have already seen the consequences in a case where my client, a small-town pharmacist in rural Georgia, is being prosecuted for a $175,000 billing error that resulted from a software malfunction, despite the fact that she self-reported the error to Medicare within 30 days and repaid the full amount with interest. Under the task force's directive, the local U.S. Attorney's Office had no choice but to refer the case to the task force, which has now indicted her under 18 U.S.C. § 1347 for healthcare fraud, a charge that carries a potential 10-year prison sentence. This case would never have been prosecuted under the traditional system, where an experienced AUSA would have recognized the absence of criminal intent and declined prosecution under the principles outlined in the Justice Manual at Section 9-27.220, which requires prosecutors to consider the likelihood of conviction, the seriousness of the offense, and the defendant's willingness to cooperate. The memorandum also violates the Equal Protection component of the Fifth Amendment's Due Process Clause by creating a system where defendants in healthcare fraud cases are treated differently from defendants in other fraud cases, such as securities fraud or bank fraud, where no similar task force mandates exist. I am currently preparing a selective prosecution motion in the pharmacist's case, arguing that the task force's directive creates a classification based solely on the type of fraud alleged, which lacks any rational basis and therefore violates the constitutional requirement that prosecutorial decisions be made on a case-by-case basis rather than through categorical directives.

The Speedy Trial Act and the Erosion of 18 U.S.C. § 3161 Protections Through Coordinated Delay

Perhaps the most insidious aspect of the Healthcare Fraud Task Force is its structural design to delay indictments while civil proceedings exhaust defendants' resources, a tactic that directly undermines the Speedy Trial Act of 1974, codified at 18 U.S.C. § 3161, which requires that a defendant be tried within 70 days of indictment or the filing of an information. The memorandum achieves this delay by directing the task force to "coordinate parallel civil and criminal proceedings" and to "delay criminal indictment until civil discovery is substantially complete," a provision that I believe is facially unconstitutional because it uses the civil process to evade the Speedy Trial Act's time limits. In practice, what this means is that a healthcare provider who is under investigation will receive a civil investigative demand under 42 U.S.C. § 1320a-7a(j) requiring the production of millions of documents, while simultaneously facing asset freezes under 18 U.S.C. § 1345 that prevent them from paying their attorneys. The government can then delay the criminal indictment for months or even years while the civil discovery proceeds, and because no indictment has been filed, the Speedy Trial Act's clock never starts running. I have a client in the Northern District of Illinois who has been under investigation by the task force for 14 months without any indictment, but who has already spent $400,000 in legal fees responding to civil discovery demands and has lost his medical practice because the asset freeze prevents him from accessing his operating accounts. This coordinated delay tactic violates the Sixth Amendment's guarantee of a speedy trial, which the Supreme Court in Barker v. Wingo, 407 U.S. 514 (1972), held requires courts to consider the length of delay, the reason for the delay, the defendant's assertion of the right, and prejudice to the defendant. The task force's memorandum explicitly states that delay is intentional and strategic, which under Barker weighs heavily against the government and should result in dismissal of any eventual indictment. Furthermore, the memorandum's provision allowing the task force to "designate any case as a complex case" under 18 U.S.C. § 3161(h)(7)(B)(ii) without judicial review effectively gives the government unilateral authority to exclude cases from the Speedy Trial Act's time limits, a power that Congress specifically reserved for the courts. I have filed a motion in the Northern District of Illinois arguing that this provision violates the separation of powers because it delegates judicial authority to the executive branch, and I anticipate that this issue will ultimately require resolution by the Supreme Court. The bottom line for healthcare providers is this: if you receive a civil investigative demand from HHS-OIG, you must immediately assume that a criminal investigation is underway and that the government is using the civil process to build a criminal case while running out the clock on your constitutional rights.

If you or your healthcare organization is under investigation by the Healthcare Fraud Task Force, you need a defense team that understands the constitutional violations embedded in this new enforcement structure. I have spent my career on both sides of the federal criminal justice system, and I know how to challenge overreaching prosecutorial tactics that violate the rules and statutes designed to protect your rights. Contact my office today for a confidential consultation, and let me put my 25 years of experience to work defending your freedom, your license, and your livelihood against this unprecedented assault on prosecutorial boundaries.